Mitochondrial disorders and the eye

Current Opinion in Ophthalmology

Volumn 22, Issue 5, 2011, Pages 325-331

  Schrier, Samantha A ^a   Falk, Marni J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

antioxidant; apoptosis; diabetic retinopathy; mitochondria; ocular neoplasm; oxidative stress

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; CURCUMIN; EDL 155; GELATINASE A; IDEBENONE; PROHIBITIN; UNCLASSIFIED DRUG;

AGING; APOPTOSIS; AUTOSOMAL DOMINANT OPTIC ATROPHY; CHRONIC PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CLINICAL FEATURE; DIABETIC RETINOPATHY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; EXTRAOCULAR MUSCLE; EYE DISEASE; GENE DELETION; GENE MUTATION; GENE THERAPY; GENETIC SCREENING; GLAUCOMA; HUMAN; LEBER HEREDITARY OPTIC NEUROPATHY; NONHUMAN; OPTIC NERVE DISEASE; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PIGMENT DISORDER; PIGMENTARY RETINOPATHY; PRIMARY GLAUCOMA; PRIORITY JOURNAL; RETINA CELL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINOBLASTOMA; RETINOPATHY; REVIEW; TUMOR CELL; UVEA MELANOMA;

AGING; DNA, MITOCHONDRIAL; EYE DISEASES; EYE NEOPLASMS; FEMALE; GENE THERAPY; HUMANS; MACULAR DEGENERATION; MALE; MATRIX METALLOPROTEINASE 2; MITOCHONDRIAL DISEASES; MUTATION; OPHTHALMOPLEGIA; OPTIC NEUROPATHY, ISCHEMIC; RETINITIS PIGMENTOSA;

EID: 80051789652     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328349419d     Document Type: Review

References (46)

1. Falk MJ. Neurodevelopmental manifestations of mitochondrial disease. J Dev Behav Pediatr 2010;31:610-621.
2. Haas RH, Parikh S, Falk MJ, et al. Mitochondrial disease: a practical approach for primary care physicians. Pediatrics 2007;120:1326-1333. (Pubitemid 350223685)
3. Calvo S, Jain M, Xie X, et al. Systematic identification of human mitochondrial disease genes through integrative genomics. Nat Genet 2006;38:576-582.
4. Haas RH, Parikh S, Falk MJ, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab 2008;94:16-37.
5. Yu-Wai-Man P, Griffiths PG, Burke A, et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 2010;117:1538-1546, 1546 e1. This study examined 188 individuals with bilateral optic atrophy for OPA1 and OPA3 nuclear gene mutations, as well as common mitochondrial DNA gene mutations that cause LHON. Twenty-seven different OPA1 mutations were detected, establishing OPA1 as the most common genetic cause of suspected DOA. OPA3 mutations were much less common in this population.
6. Fraser JA, Biousse V, Newman NJ. The neuro-ophthalmology of mitochondrial disease. Surv Ophthalmol 2010;55:299-334.
7. Milea D, Amati-Bonneau P, Reynier P, et al. Genetically determined optic neuropathies. Curr Opin Neurol 2010;23:24-28.
8. Ferre M, Bonneau D, Milea D, et al. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mutat 2009;30:E692-E705.
9. Anikster Y, Kleta R, Shaag A, et al. Type III 3-methylglutaconic aciduria (optic atrophy plus syndrome, or Costeff optic atrophy syndrome): identification of the OPA3 gene and its founder mutation in Iraqi Jews. Am J Hum Genet 2001;69:1218-1224. (Pubitemid 33124203)
10. Huizing M, Dorward H, Ly L, et al. OPA3, mutated in 3-methylglutaconic aciduria type III, encodes two transcripts targeted primarily to mitochondria. Mol Genet Metab 2010;100:149-154.
11. Reynier P, Amati-Bonneau P, Verny C, et al. OPA3 gene mutations responsible for autosomal dominant optic atrophy and cataract. J Med Genet 2004;41:e110.
12. Amati-Bonneau P, Milea D, Bonneau D, et al. OPA1-associated disorders: phenotypes and pathophysiology. Int J Biochem Cell Biol 2009;41:1855-1865.
13. Yu-Wai-Man P, Sitarz KS, Samuels DC, et al. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum Mol Genet 2010;19:3043-3052.
14. Milone M, Younge BR, Wang J, et al. Mitochondrial disorder with OPA1 mutation lacking optic atrophy. Mitochondrion 2009;9:279-281.
15. Yu-Wai-Man P, Shankar SP, Biousse V, et al. Genetic screening for OPA1 and OPA3 mutations in patients with suspected inherited optic neuropathies. Ophthalmology 2011;118:558-563.
16. Williams PA, Morgan JE, Votruba M. Opa1 deficiency in a mouse model of dominant optic atrophy leads to retinal ganglion celldendropathy. Brain 2010;133:2942-2951.
17. Wallace DC, Singh G, Lott MT, et al. Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy. Science 1988;242:1427-1430. (Pubitemid 19008070)
18. Yu-Wai-Man P, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet 2002;39:162-169. (Pubitemid 34252551)
19. Liu XL, Zhou X, Zhou J, et al. Leber's hereditary optic neuropathy is associated with the T12338C mutation in mitochondrial ND5 gene in six Han Chinese families. Ophthalmology 2011;118:978-985.
20. Abu-Amero KK, Jaber M, Hellani A, et al. Genome-wide expression profile of LHON patients with the 11778 mutation. Br J ophthalmol 2010;94:256-259.
21. Zhang J, Zhou X, Zhou J, et al. Mitochondrial ND6 T14502C variant may modulate the phenotypic expression of LHON-associated G11778A mutation in four Chinese families. Biochem Biophys Res Commun 2010;399:647-653.
22. Kirkman MA, Yu-Wai-Man P, Korsten A, et al. Gene-environment interactions in Leber hereditary optic neuropathy. Brain 2009;132(Pt 9):2317-2326.
23. Sadun AA, Morgia CL, Carelli V. Leber's hereditary optic neuropathy. Curr Treat Options Neurol 2011;13:109-117.
24. Chinnery P E A. Results of a 6-months randomized placebo-controlled trial (RHODOS) with idebanone (Catena) in Leber's Hereditary Optic Neuropathy (LHON) [poster WIP-3]. In: Presented at the 135th Annual Meeting of the American Neurological Association; 14 September 2010; San Francisco, CA, USA.
25. Lam B, Feuer W, Abukhalil F, et al. Leber hereditary optic neuropathy gene therapy clinical trial recruitment: year 1. Arch Ophthalmol 2010;128:1129-1135. Twenty-five individuals affected with LHON and 21 G11778A mitochondrial DNA mutation carriers underwent neuro-ophthalmologic testing, including evaluation of retinal nerve fiber layer thickness, to determine particular characteristics to prioritize individuals for potential future gene therapy. Individuals with only mild damage to the retinal nerve fiber layer and low amplitude pattern electroretinogram may be good candidates for LHON gene therapy.
26. DiMauro S, Garone C. Historical perspective on mitochondrial medicine. Dev Disabil Res Rev 2010;16:106-113.
27. Almousa R, Charlton A, Rajesh ST, et al. Optimizing muscle biopsy for the diagnosis of mitochondrial myopathy. Ophthal Plast Reconstr Surg 2009;25:366-370.
28. Gronlund MA, Honarvar AK, Andersson S, et al. Ophthalmological findings in children and young adults with genetically verified mitochondrial disease. Br J ophthalmol 2010;94:121-127. This retrospective study examined 59 individuals with primary mitochondrial disease to delineate the frequency of various ophthalmologic findings within the probands. Ocular disorders were detected in 81% of the cohort, stressing the importance of regular ophthalmologic screening in individuals with suspected or verified mitochondrial disease.
29. Pfeffer G, Sirrs S, Wade NK, et al. Multisystem disorder in late-onset chronic progressive external ophthalmoplegia. Can J Neurol Sci 2011;38:119-123.
30. Jarrett SG, Lewin AS, Boulton ME. The importance of mitochondria in agerelated and inherited eye disorders. Ophthalmic Res 2010;44:179-190.
31. Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab Invest 2010;90:1365-1372. This study examined the effects of MMP2 inhibition in diabetic mice, clarifying MMP2 as playing a significant role in cellular apoptosis, as well as elaborating the potential therapeutic role for MMP2 inhibitors in diabetic retinopathy.
32. Mohammad G, Kowluru RA. Novel role of mitochondrial matrix metalloproteinase-2 in the development of diabetic retinopathy. Invest Ophthalmol Vis Sci 2011;52:3832-3841.
33. Lee H, Arnouk H, Sripathi S, et al. Prohibitin as an oxidative stress biomarkerin the eye. Int J Biol Macromol 2010;47:685-690.
34. Madsen-Bouterse SA, Zhong Q, Mohammad G, et al. Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. Free Radic Res 2010;44:313-321. This study confirmed the deleterious effects of oxidative stress on retinal cells, highlighting a possible therapeutic role of increasing the antioxidant scavenging enzyme, MnSOD.
35. Li J, Chen X, Xiao W, et al. Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells. Biochem Biophys Res Commun 2010;404:349-356. SS31, a mitochondrial antioxidant peptide, was analyzed for its effect on human retinal endothelial cells exposed to high-glucose environments, as seen in diabetic retinopathy. Cells treated with SS31 were found to have significantly less oxidative stress and lower levels of cytochrome c.
36. Osborne NN, Kamalden TA, Majid AS, et al. Light effects on mitochondrial photosensitizers in relation to retinal degeneration. Neurochem Res 2010;35:2027-2034.
37. Kenney MC, Atiliano SR, Boyer D, et al. Characterization of retinal and blood mitochondrial DNA from age-related macular degeneration patients. Invest Ophthalmol Vis Sci 2010;51:4289-4297. The authors examined the mtDNA in retina and blood from AMD patients and normal controls. They identified higher levels of large mitochondrial DNA genome deletions and rearrangements in the retinas of the AMD population.
38. Lee S, Van Bergen NJ, Kong GY, et al. Mitochondrial dysfunction in glaucoma and emerging bioenergetic therapies. Exp Eye Res 2010. [Epub ahead of print]
39. Osborne NN. Mitochondria: their role in ganglion cell death and survival in primary open angle glaucoma. Exp Eye Res 2010;90:750-757.
40. Ju WK, Kim KY, Duong-Polk KX, et al. Increased optic atrophy type 1 expression protects retinal ganglion cells in a mouse model of glaucoma. Mol Vis 2010;16:1331-1342. This study examined the protective effects on retinal ganglion cells of overexpression of OPA1. Cells transfected with OPA1 showed longer survival and decreased rates of apoptosis.
41. Wolf C, Gramer E, Müller-Myhsok B, et al. Evaluation of nine candidate genes in patients with normal tension glaucoma: a case-control study. BMC Med Genet 2009;10:91.
42. Tanwar M, Dada T, Sihota R, et al. Mitochondrial DNA analysis in primary congenital glaucoma. Mol Vis 2010;16:518-533.
43. Broaddus E, Topham A, Singh AD. Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 2009;93:24-27.
44. Nassr M, Wang X, Mitra S, et al. Treating retinoblastoma in tissue culture and in a rat model with a novel isoquinoline derivative. Invest Ophthalmol Vis Sci 2010;51:3813-3819. EDL-55, a tetrahydroisoquinoline derivative, given in vivo to treat retinoblastoma in rat pups significantly attenuated tumor growth. Additionally, EDL-55 was shown to induce apoptosis within in-vitro treated cells.
45. Lu C, Song E, Hu DN, et al. Curcumin induces cell death in human uveal melanoma cells through mitochondrial pathway. Curr Eye Res 2010;35:352-360.
46. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23:363-398. (Pubitemid 36361976)